With Its Hypertension Franchise in Crisis, Novartis Restructures
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.
You may also be interested in...
Tekturna’s Loss May Be Entresto’s Gain As Novartis Hopes For Change In The ATMOSPHERE
Strength of Novartis’ new heart failure drug Entresto contrasts with yet another failed outcomes study for its old renin inhibitor Tekturna.
Actavis Hypertension Combo Prompts Discussion Of “Me-Too” Drug Standards
FDA’s Cardiovascular and Renal Drugs Advisory Committee used much of its review of a nebivolol/valsartan combo pill to discuss how much of an improvement a “me-too” product should offer over predecessors and a minimum clinical benefit threshold for antihypertensives.
FDA Keeps Calcitonin Products On The Market But Narrows Osteoporosis Claim
Saying its review found “no conclusive evidence of a causal relationship” between the products and cancer, agency is allowing continued marketing of Miacalcin and Fortical nasal sprays but limiting use to only those post-menopausal women for whom alternative treatments are not suitable.